期刊文献+

间充质干细胞在瘢痕形成及治疗应用中的研究进展

Research Progress of Mesenchymal Stem Cells in Scar Formation and Therapeutic Applications
下载PDF
导出
摘要 瘢痕是机体皮肤组织受到创伤或烧伤等不良应激后引发受损部位发生一系列的损伤修复反应,最终以结缔组织修复而告终,形成一种与正常皮肤结构和功能不完全相同的组织形式。间充质干细胞(MSCs)能够分泌各种生长因子,促进细胞的再生和修复过程,且可以促进瘢痕组织内血管生成,减轻局部炎症反应;降解异常堆积的胶原,重塑瘢痕组织;对局部组织的免疫功能具有双向调节作用。因此,MSCs应用于瘢痕的防治具有广阔的应用前景。该文回顾近年发表的文献,从MSCs对瘢痕组织治疗机制的再生愈合、抗炎效应、抗纤维化作用、免疫调节等研究方向及临床应用做一综述。 Cicatrix is a series of damage and repair reactions in the damaged part after the body’s skin tissue is subjected to trauma or burns and other adverse stresses,and finally ends in connective tissue repair,forming a tissue form that is not exactly the same as normal skin structure and function.Mesenchymal stem cells(MSCs)can secrete various growth factors,promote cell regeneration and repair,and can promote angiogenesis in cicatrix tissues and reduce local inflammation;degrade abnormally accumulated collagen and reshape cicatrix tissue;it has a two-way regulatory effect on the immune function of local tissues.Therefore,the application of MSCs in the prevention and treatment of cicatrix has broad application prospects.This article reviews the literature published in recent years,and reviews the research directions and clinical applications of MSCs on cicatrix tissue treatment mechanisms such as regeneration and healing,anti-inflammatory effects,anti-fibrosis effects,and immune regulation.
作者 范永梅 吕开阳 曾跃勤 刘文军 Fan Yongmei;Lv Kaiyang;Zeng Yueqin;Liu Wenjun(Department of Burn Surgery,Second Affiliated Hospital of Kunming Medical University,Kunming 650101,China;Biomedical Engineering Research Center of Kunming Medical University,Kunming 650101,China)
出处 《哈尔滨医药》 2023年第1期128-131,共4页 Harbin Medical Journal
基金 国家自然科学基金委员会资助项目(81660319) 国家自然科学基金委员会资助项目(82060349) 云南省科技厅科技计划项目(2018FE001(-242))。
关键词 间充质干细胞 瘢痕形成 治疗应用 Mesenchymal stem cells Scar formation Therapeutic application
  • 相关文献

参考文献4

二级参考文献58

  • 1Gauglitz GG, Korting HC, Pavicic T, et al. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med, 2011,17 ( 1/2 ) : 113-125.
  • 2Bloemen MC, van der Veer WM, Ulrich MM, et al. Prevention and curative management of hypertrophic scar formation. Burns, 2009,35 (4) :463-475.
  • 3Aarabi S, Longaker MT, Gurtner GC. Hypertrophic scar formation following burns and trauma: new approaches to treatment. PLoS Med, 2007,4(9) :e234.
  • 4Brown JJ, Bayat A. Genetic susceptibility to raised dermal scarring. BrJDermatol, 2009,161(1) :8-18.
  • 5Marneros AG, Norris JE, Olsen BR, et al. Clinical genetics of familial keloids. Arch Dermatol, 2001,137 ( 11 ) : 1429-1434.
  • 6Chen Y, Gao JH, Liu XJ, et al. Characteristics of occurrence for Han Chinese familial keloids. Burns, 2006,32 (8) : 1052-1059.
  • 7Marneros AG, Norris JE, Watanabe S, et al. Genome scans provide evidence for keloid susceptibility loci on chromosomes 2q23 and 7p11. J Invest Dermatol, 2004,122 ( 5 ) : 1126-1132.
  • 8Hinz B. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol, 2007,127 (3) :526-537.
  • 9Wang J, Dodd C, Shankowsky HA, et al. Deep dermal fibroblasts contribute to hypertrophic scarring. Lab Invest, 2008,88 (12) :1278-1290.
  • 10Werner S, Krieg T, Smola H. Keratinocyte-fibroblast interactions in wound healing. J Invest Dermatol, 2007,127 (5) :998-1008.

共引文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部